You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Public Rights-of-Way Assessment Instrumentation to Determine Accessibility

    SBC: BENEFICIAL DESIGNS INC            Topic: 081FH2

    City planners and engineers need detailed assessments of public rights-of-way to evaluate existing conditions, determine compliance with draft accessibility guidelines, and plan reconstruction projects. Current assessment methods are inadequate and inefficient due to the time and resources required. This project will develop an automated public rights-of-way assessment process and the measuremen ...

    SBIR Phase II 2010 Department of Transportation
  2. SapC-DOPS nanovesicles for Treating Glioblastoma Multiforme

    SBC: BEXION PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Our goal is to develop a new molecular entity with a novel mechanism of action for targeting and eliminating glioblastoma multiforme (GBM, high grade glioma), a deadly and invasive brain tumor with no effective treatment. Of the 12,000 patients expected to be diagnosed with GBM this year, most will succumb within the first year. Clearly, there is an urgent ...

    SBIR Phase II 2010 Department of Health and Human Services
  3. Injectable collagen crosslink augmentation for degenerative disc disease

    SBC: ORTHOPEUTICS, LP            Topic: NIAMS

    DESCRIPTION (provided by applicant): With regard to prevalence and cost to society, low-back pain has few peers. With a patient population in excess of 15 million/year, the societal cost is estimated to be in the realm of 100 billion/year. Current treatment options for this disease have shown limited success, including physical therapy, medication and surgery. This proposal involves a novel, nons ...

    SBIR Phase II 2010 Department of Health and Human Services
  4. Development of a Personalized Medicine Interface for the Safe and Effective Treat

    SBC: PHARMACOGENETICS DIAGNOSTIC LABORATORIES            Topic: NHLBI

    DESCRIPTION (provided by applicant): Improvements in the safety and efficacy of warfarin therapy will result from intelligent application of knowledge derived from inherited characteristics (CYP2C9 and VKORC1) of individual patients, only when this knowledge is applied through a standardized interventional approach. The fundamental pharmacologic influences of CYP2C9 and VKORC1 have been unequi ...

    SBIR Phase II 2010 Department of Health and Human Services
  5. Creation of hyperactive transposons for mutagenesis in rodents

    SBC: TRANSPOSAGEN BIOPHARMACEUTICALS, INC.            Topic: NCRR

    DESCRIPTION (provided by applicant): The rat is a favored model for many types of human disease for which mice are not suitable. As opposed to the mouse, rats and humans also share more similarity in their cytochrome P450 genes, making the rat a more useful model for toxicology and pharmacology studies. The rat is also a favored model for diabetes, arthritis, behavioral disorders (including drug a ...

    SBIR Phase II 2010 Department of Health and Human Services
  6. Portable pneumatic driver for counterpulsation therapy

    SBC: SCR, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): SCR, Inc. (Louisville, KY) is developing a chronic implantable CPD system to treat HF patients who may be responsive to long-term counterpulsation support. The CPD has been developed for superficial implantation via a pacemaker incision without the need to enter the chest and enables complete patient mobility. The CPD is a 32-ml stroke volume polyurethane-lined ...

    SBIR Phase II 2009 Department of Health and Human Services
  7. Genomic Biomarkers for Neuropsychiatric Illnesses

    SBC: SUREGENE, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The long-term objective of this project is to develop validated, genetic biomarkers to aid in more accurate diagnosis and targeted treatment of schizophrenia and related neuropsychiatric illnesses, including bipolar disorder. In Phase I, SureGene demonstrated the feasibility of using specific dimensions of mental illness to discover novel genes and genetic var ...

    SBIR Phase II 2009 Department of Health and Human Services
  8. PHASE II TOPIC 233: AUTOMATED PROCESSING OF CANCER-RELATED DATA

    SBC: QUANTUMMARK LLC            Topic: N/A

    Location 1860 WENDY WAY RENO, NV 89509 United States N44CO200900040 $749 996.00 2 009 PHASE II TOPIC 233: AUTOMATED PROCESSING OF CANCER-RELATED DATA Department of Health and Human Services SBIR PHS2009-1 QUANTUMMARK LLC Phase II N44CO200900040 1 ...

    SBIR Phase II 2009 Department of Health and Human Services
US Flag An Official Website of the United States Government